Leigh Steinberg
CIK: 0002153157
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
FBLG
FibroBiologics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Steinberg Leigh
Steinberg Leigh (SEC CIK 0002153157) files insider reports with the SEC as Director of FibroBiologics, Inc. (FBLG).
Signal8 holds 1 ownership filing by Steinberg Leigh, a Form 3, filed on Sep 1, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Steinberg Leigh's filings is in HOUSTON, TX.
Other insiders filing for FibroBiologics, Inc. (FBLG)
- Khoja Hamid, Chief Scientific Officer
- Rubins Kathleen Hallisey, Director
- Hoffman Robert E., Director
- Cilento Richard C. Jr., Director
- Link Matthew, Director
- Niklas Victoria Ninon Olivia, Director